hsa‑miR‑455‑3P as a predictive biomarker of anemia in patients with non‑small cell lung cancer treated with carboplatin plus paclitaxel

IF 2.5 4区医学 Q3 ONCOLOGY

Oncology Letters Pub Date : 2024-03-21 DOI:10.3892/ol.2024.14350

Pedro Vasconcelos, Cecília S Seguin, A. Barbeiro, Lair Zambon, Helen Honma, Aurício Perroud Jr, Murilo Geraldo, E. Pincinato, Patricia Moriel

引用次数: 0

查看原文本刊更多论文

hsa-miR-455-3P 作为卡铂加紫杉醇治疗非小细胞肺癌患者贫血的预测性生物标记物

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology Letters ONCOLOGY-

CiteScore

5.70

自引率

0.00%

发文量

412

审稿时长

2.0 months

期刊介绍： Oncology Letters is a monthly, peer-reviewed journal, available in print and online, that focuses on all aspects of clinical oncology, as well as in vitro and in vivo experimental model systems relevant to the mechanisms of disease. The principal aim of Oncology Letters is to provide the prompt publication of original studies of high quality that pertain to clinical oncology, chemotherapy, oncogenes, carcinogenesis, metastasis, epidemiology and viral oncology in the form of original research, reviews and case reports.